A Phase 2 interventional study of Domvanalimab and Quemliclustat in Advanced Non-Small Cell Lung Cancer, sponsored by Gilead Sciences. Active, not recruiting at 53 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
The study includes multiple substudy arms (Substudy A, B, C), which will evaluate immunotherapy-based combinations.
Gilead Sciences is the lead sponsor of 680 studies on the registry; 24 are open to participants now.
Of its 259 completed or terminated interventional studies of FDA-regulated products, 249 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Domvanalimab and Zimberelimab, both administered by IV infusion
Drug: Domvanalimab · Drug: Zimberelimab
Domvanalimab and Zimberelimab, both administered by IV infusion
Drug: Domvanalimab · Drug: Zimberelimab
Quemliclustat and Zimberelimab, both administered by IV infusion
Drug: Quemliclustat · Drug: Zimberelimab
Quemliclustat, zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
Drug: Quemliclustat · Drug: Zimberelimab · Drug: Platinum-Based Doublet
Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
Drug: Domvanalimab · Drug: Zimberelimab · Drug: Platinum-Based Doublet
Domvanalimab, Quemliclustat, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
Drug: Domvanalimab · Drug: Quemliclustat · Drug: Zimberelimab · Drug: Platinum-Based Doublet
Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
Drug: Domvanalimab · Drug: Zimberelimab · Drug: Platinum-Based Doublet
Domvanalimab, Zimberelimab, and platinum doublet chemotherapy, all administered by IV infusion
Drug: Domvanalimab · Drug: Zimberelimab · Drug: Platinum-Based Doublet
Quemliclustat, Zimberelimab, and Docetaxel, all administered by IV infusion
Drug: Quemliclustat · Drug: Zimberelimab · Drug: Docetaxel
Domvanalimab, Zimberelimab, and Docetaxel, all administered by IV infusion
Drug: Domvanalimab · Drug: Zimberelimab · Drug: Docetaxel
Administered as specified in the treatment arm
Administered as specified in the treatment arm
Administered as specified in the treatment arm
Administered as specified in the treatment arm
Administered as specified in the treatment arm
Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time frame: Up to 58 months
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Time frame: Up to 58 months
Overall Survival (OS)
Time frame: From date of first dose until the date of death due to any cause (approximately 58 months)
Progression-free Survival (PFS) as determined by the Investigator according to RECIST v1.1
Time frame: Up to 58 months
Disease Control Rate (DCR)
Time frame: Up to 58 months
Duration of response (DoR) as determined by the Investigator according to RECIST v1.1
Time frame: Up to 58 months
Investigational study treatments peak plasma or serum concentration (Cmax)
Time frame: Up to 58 months
Investigational study treatments time of peak concentration (Tmax)
Time frame: Up to 58 months
Investigational study treatments area under the plasma or serum concentration versus time curve (AUC)
Time frame: Up to 58 months
Percentage of biologic treatment-emergent antidrug-antibody (ADA)-positive participants and ADA-negative participants
Time frame: Up to 58 months
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gilead Sciences